[HTML] springer.comFull View

[HTML][HTML] Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - Genome medicine, 2020 - Springer
Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …
被引用次数：113 相关文章

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Long, Z Zhang… - Genome …, 2020 - search.proquest.com
Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …
[HTML] nih.gov

[HTML][HTML] Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - Genome …, 2020 - ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …
[HTML] biomedcentral.com

[HTML][HTML] Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang… - Genome …, 2020 - genomemedicine.biomedcentral …
Immune checkpoint blockade (ICB) therapy has demonstrated considerable clinical benefit
in several malignancies, but has shown favorable response in only a small proportion of …

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - Genome …, 2020 - europepmc.org
Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang… - Genome …, 2020 - mdanderson.elsevierpure.com
Background: Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …
[PDF] researchgate.net

[PDF][PDF] Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - pathways, 2020 - researchgate.net
Background: Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - Genome …, 2020 - go.gale.com
Background Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …
[PDF] archive.org

[PDF][PDF] Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang, Y Zhang… - …, 2020 - scholar.archive.org
Background: Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.

Y Ye, X Kuang, Z Xie, L Liang, Z Zhang… - Genome …, 2020 - search.ebscohost.com
Background: Immune checkpoint blockade (ICB) therapy has demonstrated considerable
clinical benefit in several malignancies, but has shown favorable response in only a small …